flashContent
Company news

15 February 2017

"Trans-Technologies" Ltd (a part of «Alkor Bio» Group) receives European patent "Biotransplant for cellular therapy based on mesenchymal bone marrow stem сells"

9th November 2016 the European Patent Office granted the patent "Biotransplant for cellular therapy based on mesenchymal bone marrow stem сells for "Trans-Technologies" Ltd (Alkor Bio Group of Companies)". The patent application describes derivation of culture of human mesenchymal stem cells from bone marrow and using them for production of corresponding biotransplant. The invention refers to the field of cellular therapy and tissue engineering and may potentially be used, for instance, in treatment of various ischaemic diseases.

The invention considered new indeed, that is especially remarkable due to the tough competition in the human stem cell research field in European Union.

Elena Gershina, The Head of the "Trans-Technologies" stem cells Bank, says:

"Once the patent is granted we have to validate it in the European countries where we would like to get patent protection. In addition to Germany, we consider Great Britain, France and Switzerland. The patent covers the method of mesenchymal stem cells isolation, purification, culture  and corresponding biotransplant production. The latter can be used for treatment of various pathologic states, in particular, in therapy of severe tissue injuries after ischemic stroke, heart attack, brain trauma".

At present, "Trans-Technologies" is carrying out two related research projects at the Newcastle University Institute of Neuroscience (Newcastle upon Tyne, United Kingdom). The first study, "Preclinical assessment of the multipotent human mesenchymal bone marrow stromal cells therapy for ischaemic stroke ", is to prove  therapeutic effect and give the green light to clinical trials. The second project, “Investigation of the gene expression profiles in brain tissue after ischaemic stroke in rats”, focuses on comparative study of the gene expression profiles in the brain tissue in animals receiving stem cell therapy. It will help to specify the mechanism of these stem cells action and their potential therapeutic targets in the damaged tissue. Both projects are carried out in the strictly controlled conditions, on inbred animal strains, and conform to the highest quality standards.

   

Elena Gershina:

“When the preclinical study is completed, we are starting the clinical trials of our biotransplant. Next, having the European patent and clinical trials results, we will be able to register our product and sell it in Europe.

It is worth noting that "Trans-Technologies» first produced the mesenchymal stem cell-based biotransplant as early as in 2006. The decision to set out for Europe was made because Russian regulations and guidelines governing cell based therapies and products are mainly prohibitory. The Federal Law ‘On Biomedical Cell Products’, aimed at developing the sector of biomedical technologies in Russia, was adopted only in 2016. Unfortunately, it does not clarify once and for all neither the legal status of cell-based products, nor their registration procedure. On the contrary, EU have clear and understandable registration procedures for hi-tech medicinal products, including cell-based ones”.

“Trans-Technologies”, founded in 2002, is now a part of “Alkor Bio” Group, the largest biotechnological company in the Northwest Russia. The main goal of “Trans-Technologies” is developing and implementation in clinic stem-cell based medicinal products. In 2005, “Trans-Technologies” was first to open stem cells bank in Saint Petersburg and started to provide a full range of cord blood storage services.  At present, “Trans-Technologies” is the only biotech company in Northwest Russia working with human stem cells in high performance class B cleanroom.

Moreover, "Trans-Technologies" Ltd  holds 8 Russian patents:

№ 2296328 issued 27.03.2007 "Method of determining susceptibility to cancer and a diagnostic kit for its implementation"

№ 2303632 issued 27.07.2007 "Method of obtaining mesenchymal stem cells from bone marrow of mammals and the population of mesenchymal stem cells obtained in this way"

№ 2303631 issued 27.07.2007 "The medium for cryopreservation of mesenchymal stem cells and biotransplantat with its use"

№ 2303462 issued 27.07.2007 "Biotransplantat and method of treatment of mental retardation"

№ 2309756 issued 10.11.2007 "Method of treatment of false joints by transplantation of autologous mesenchymal stem cells. Biotransplantat for its application"

№ 2370227 issued 20.10.2009 "Method of treatment of multisplintered and multiple fractured of long tubular bones"

№ 2368338 issued 20.10.2009 "Method of reconstruction of periodontal tissues"  

№ 2430743 issued 10.10.2011 "Biologically active wound dressing"